{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maintenance+Dose+Arm&page=2", "query": { "intervention": "Maintenance Dose Arm", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Maintenance+Dose+Arm&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T01:04:42.207Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04469556", "title": "Pancreatic Adenocarcinoma Signature Stratification for Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer Metastatic", "Pancreatic Ductal Adenocarcinoma", "Advanced Pancreatic Cancer" ], "interventions": [ { "name": "Folfirinox", "type": "DRUG" }, { "name": "Gemcitabine/nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University Health Network, Toronto", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2020-10-14", "completion_date": "2025-03-05", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-09-22T01:04:42.207Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04469556" }, { "nct_id": "NCT00948922", "title": "Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Autologous Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Allogeneic Stem Cell Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2009-06-18", "completion_date": "2019-05-14", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-09-22T01:04:42.207Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00948922" }, { "nct_id": "NCT03570619", "title": "Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer", "Metastatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2018-12-14", "completion_date": "2024-03-26", "has_results": true, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-09-22T01:04:42.207Z", "location_count": 8, "location_summary": "San Diego, California • San Francisco, California • Tampa, Florida + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03570619" }, { "nct_id": "NCT04165070", "title": "KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Vibostolimab", "type": "BIOLOGICAL" }, { "name": "Boserolimab", "type": "BIOLOGICAL" }, { "name": "MK-4830", "type": "BIOLOGICAL" }, { "name": "MK-0482", "type": "BIOLOGICAL" }, { "name": "Ifinatamab Deruxtecan (I-DXd)", "type": "BIOLOGICAL" }, { "name": "HER3-DXd", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2019-12-19", "completion_date": "2032-10-13", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-22T01:04:42.207Z", "location_count": 18, "location_summary": "Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04165070" }, { "nct_id": "NCT05704361", "title": "A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "RO7121932 IV", "type": "DRUG" }, { "name": "RO7121932 SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 119, "start_date": "2021-08-11", "completion_date": "2027-07-08", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-22T01:04:42.207Z", "location_count": 2, "location_summary": "Stanford, California • New Haven, Connecticut", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05704361" }, { "nct_id": "NCT06937307", "title": "Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Kidney Injury", "Cirrhosis", "Decompensated Cirrhosis of Liver" ], "interventions": [ { "name": "Droxidopa capsules", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Giuseppe Cullaro, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 75, "start_date": "2025-05-27", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-22T01:04:42.207Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06937307" }, { "nct_id": "NCT00292110", "title": "Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opiate-Related Disorders", "Cocaine-Related Disorders" ], "interventions": [ { "name": "Methadone", "type": "DRUG" }, { "name": "Contingency Management", "type": "BEHAVIORAL" }, { "name": "Methadone dose", "type": "DRUG" }, { "name": "Contingency Management/Noncontingent Incentives", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "National Institute on Drug Abuse (NIDA)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 140, "start_date": "2004-02-01", "completion_date": "2013-08-09", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-09-22T01:04:42.207Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00292110" }, { "nct_id": "NCT05253209", "title": "A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ventricular Septal Defect", "Atrioventricular Septal Defect", "Primum Atrial Septal Defect" ], "interventions": [ { "name": "L-citrulline", "type": "DRUG" }, { "name": "Plasmalyte A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asklepion Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 64, "start_date": "2022-06-29", "completion_date": "2024-05-10", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-22T01:04:42.207Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05253209" }, { "nct_id": "NCT03558152", "title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "UTTR1147A", "type": "DRUG" }, { "name": "UTTR1147A Placebo", "type": "DRUG" }, { "name": "Vedolizumab", "type": "DRUG" }, { "name": "Vedolizumab Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 195, "start_date": "2018-10-26", "completion_date": "2021-12-15", "has_results": true, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-09-22T01:04:42.207Z", "location_count": 2, "location_summary": "Greenville, North Carolina • Salt Lake City, Utah", "locations": [ { "city": "Greenville", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03558152" }, { "nct_id": "NCT07553299", "title": "A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity", "Overweight", "Weight Maintenance" ], "interventions": [ { "name": "VRB-101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verdiva Bio Dev Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 120, "start_date": "2026-06-12", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-09-22T01:04:42.207Z", "location_count": 20, "location_summary": "Cullman, Alabama • Phoenix, Arizona • Tempe, Arizona + 16 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07553299" } ] }